Ken Griffin
TXG icon

Ken Griffin’s 10x Genomics TXG Stock Holding History

Ken Griffin’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.71M Buy
174,700
+67,600
+63% +$1.35M ﹤0.01% 4854
2025
Q4 		$1.75M Buy
107,100
+41,300
+63% +$624K ﹤0.01% 6198
2025
Q3 		$769K Sell
65,800
-81,200
-55% -$1.06M ﹤0.01% 8119
2025
Q2 		$1.7M Buy
147,000
+3,800
+3% +$34.6K ﹤0.01% 6025
2025
Q1 		$1.25M Buy
143,200
+102,300
+250% +$1.29M ﹤0.01% 6465
2024
Q4 		$587K Sell
40,900
-24,600
-38% -$388K ﹤0.01% 8200
2024
Q3 		$1.48M Buy
65,500
+39,300
+150% +$812K ﹤0.01% 6084
2024
Q2 		$510K Sell
26,200
-82,100
-76% -$2.15M ﹤0.01% 8000
2024
Q1 		$4.06M Buy
108,300
+5,200
+5% +$228K ﹤0.01% 4270
2023
Q4 		$5.77M Sell
103,100
-39,300
-28% -$1.71M ﹤0.01% 3584
2023
Q3 		$5.87M Buy
142,400
+40,200
+39% +$2.09M ﹤0.01% 3399
2023
Q2 		$5.71M Buy
102,200
+31,500
+45% +$1.7M ﹤0.01% 3443
2023
Q1 		$3.94M Buy
70,700
+51,100
+261% +$2.39M ﹤0.01% 4188
2022
Q4 		$714K Sell
19,600
-49,200
-72% -$1.61M ﹤0.01% 7498
2022
Q3 		$1.96M Buy
68,800
+37,500
+120% +$1.43M ﹤0.01% 5629
2022
Q2 		$1.42M Sell
31,300
-35,300
-53% -$1.83M ﹤0.01% 6245
2022
Q1 		$5.07M Sell
66,600
-4,000
-6% -$350K ﹤0.01% 4146
2021
Q4 		$10.5M Buy
70,600
+30,900
+78% +$4.73M ﹤0.01% 2998
2021
Q3 		$5.78M Buy
39,700
+7,800
+24% +$1.34M ﹤0.01% 4033
2021
Q2 		$6.25M Buy
31,900
+4,700
+17% +$851K ﹤0.01% 3970
2021
Q1 		$4.92M Sell
27,200
-5,100
-16% -$881K ﹤0.01% 4292
2020
Q4 		$4.57M Sell
32,300
-400
-1% -$58K ﹤0.01% 3844
2020
Q3 		$4.08M Buy
32,700
+8,500
+35% +$892K ﹤0.01% 3460
2020
Q2 		$2.16M Sell
24,200
-6,300
-21% -$491K ﹤0.01% 4430
2020
Q1 		$1.9M Buy
30,500
+15,600
+105% +$1.22M ﹤0.01% 4219
2019
Q4 		$1.14M Buy
+14,900
New +$896K ﹤0.01% 5362

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ken Griffin's TXG Position: Q1 2026 in Review

Ken Griffin increased its 10x Genomics (TXG) stake by 469% in Q1 2026, buying an estimated $12.3M and bringing the position to 743,734 shares worth $15.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2622.

Ken Griffin first reported a position in TXG in Q3 2019 and has held it in 25 quarters since. The position peaked at $68.6M in Q1 2023. 330 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Ken Griffin held 743,734 shares of 10x Genomics worth $15.8M as of Q1 2026.
  • Ken Griffin bought 612,914 10x Genomics shares in Q1 2026, an estimated $12.3M.
  • 10x Genomics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #2622 holding.
  • Ken Griffin first reported a position in 10x Genomics in Q3 2019 and has held it in 25 quarters since.
  • Ken Griffin's 10x Genomics position peaked at $68.6M in Q1 2023.
  • 330 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.